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Abstract
Objectives: To identify biomarkers of renal disease in adolescents with type 1
diabetes (T1D) and to compare findings in adults with T1D.
Methods: Twenty-five serum biomarkers were measured, using a Luminex platform,
in 553 adolescents (median [interquartile range] age: 13.9 [12.6, 15.2] years), rec-
ruited to the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial. Associa-
tions with baseline and final estimated glomerular filtration rate (eGFR), rapid decliner
and rapid increaser phenotypes (eGFR slopes <−3 and > 3 mL/min/1.73m2/year,
respectively), and albumin-creatinine ratio (ACR) were assessed. Results were also
Abbreviations: ACR, albumin/creatinine ratio; AdDIT, Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial; AUC, area under the receiver operator characteristic curve; eGFR, estimated
glomerular filtration rate; ESRD, end-stage renal disease; IQR, interquartile range; SDRNT1BIO, Scottish Diabetes Research Network Type 1 Bioresource.
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compared with those obtained in 859 adults (age: 55.5 [46.1, 64.4) years) from the
Scottish Diabetes Research Network Type 1 Bioresource.
Results: In the adolescent cohort, baseline eGFR was negatively associated with tre-
foil factor-3, cystatin C, and beta-2 microglobulin (B2M) (B coefficient[95%CI]: −0.19
[−0.27, −0.12], P = 7.0 × 10−7; −0.18 [−0.26, −0.11], P = 5.1 × 10−6; −0.12 [−0.20,
−0.05], P = 1.6 × 10−3), in addition to clinical covariates. Final eGFR was negatively
associated with osteopontin (−0.21 [−0.28, −0.14], P = 2.3 × 10−8) and cystatin C
(−0.16 [−0.22, −0.09], P = 1.6 × 10−6). Rapid decliner phenotype was associated with
osteopontin (OR: 1.83 [1.42, 2.41], P = 7.3 × 10−6), whereas rapid increaser pheno-
type was associated with fibroblast growth factor-23 (FGF-23) (1.59 [1.23, 2.04],
P = 2.6 × 10−4). ACR was not associated with any of the biomarkers. In the adult
cohort similar associations with eGFR were found; however, several additional bio-
markers were associated with eGFR and ACR.
Conclusions: In this young population with T1D and high rates of hyperfiltration,
osteopontin was the most consistent biomarker associated with prospective changes
in eGFR. FGF-23 was associated with eGFR increases, whereas trefoil factor-3,
cystatin C, and B2M were associated with baseline eGFR.
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1 | INTRODUCTION
Diabetic kidney disease remains a major determinant of morbidity and
mortality for people with type 1 diabetes, being the leading cause of
end stage renal disease (ESRD) and a key risk factor for cardiovascular
disease.1,2 This complication is characterized by progressive increases
in urinary albumin excretion associated in some populations with ini-
tial hyperfiltration and subsequent declines in glomerular filtration
rate (GFR), which can occur following different patterns and at vari-
able rates over the lifetime of people with diabetes.3,4
In adolescents with type 1 diabetes, advanced stages of diabetes
kidney disease, such as proteinuria and clinically relevant reductions
in GFR are rare compared to adults, whereas earlier stages, such as
hyperfiltration and subclinical increases in urinary albumin excretion,
reflecting renal functional and structural changes, can be common.3,5,6
Previous studies in adolescent cohorts with type 1 diabetes have
shown rates of hyperfiltration from 10% to 50%,3,7-9 and identified
increased GFR during puberty as an independent predictor of albu-
minuria and later decline in GFR.3,8,9 Increased GFR in adolescents
reflects the effect of hyperglycemia on renal hemodynamics, but is
also strongly influenced by pubertal hormonal changes,3,8 which have
also been associated with increases in renal size.3
Biomarkers to identify adolescents at risk of renal complications
at an early stage are needed, to guide screening strategies as well as
to help in stratifying subjects for future intervention trials.10 Up to
now individual or panels of biomarkers for advanced stages of diabe-
tes kidney disease have been mainly investigated in adult
populations.10 It remains unknown if the same biomarkers could have
a similar predictive role in younger population with type 1 diabetes
and during earlier stages of renal disease.10
The aims of the present study were: (a) to explore a set of bio-
markers, which we recently assessed in adults with type 1 diabetes,11
in relation to changes in GFR and urinary albumin excretion, in a
cohort of adolescents with type 1 diabetes, and (b) to compare the
associations between biomarkers and renal outcomes between ado-
lescents and adults with type 1 diabetes.
2 | METHODS
2.1 | Study design and population
The overall design of the Adolescent Type 1 Diabetes Cardio-Renal
Intervention Trial (AdDIT) studies has been previously reported.6,12,13
Briefly, between 2009 and 2013, 443 adolescents (10-16 years) with
a urinary albumin-creatinine ratio (ACR) in the upper tertile of the nor-
mal range (high-ACR group) were randomized to an ACE inhibitor
(Quinapril) or matching placebo, and separately to a statin
(Atorvastatin) or matching placebo in a 2 × 2 factorial design over a
2-4-year treatment period, until March 2016. During the same time-
frame, 404 adolescents with an ACR in the middle or lower tertiles
(low-ACR group) were recruited to the parallel AdDIT Observational
study. Both groups underwent similar baseline and follow-up assess-
ments, based on a standardized protocol.6,12
For the present study, the study population consisted of 553 ado-
lescents with type 1 diabetes, representing a subgroup of those
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recruited into the AdDIT Trial and parallel Observational study, with
available samples for the present analysis.
The study sponsor was the University of Cambridge and Cam-
bridge University Hospitals NHS Foundation Trust. The study proto-
col conformed to the Declaration of Helsinki and was approved by
the Cambridge University Hospitals and participating research ethics
committees. Parents of participants provided written informed con-
sent, and study participants were asked to provide their assent, until
they reached an age when they could consent to study follow-up.
2.1.1 | Baseline assessment
Baseline visits for participants recruited to both the Trial and Obser-
vational arms of AdDIT included measurement of height, weight, waist
circumference, arterial blood pressure. Non-fasting blood samples
were collected for local HbA1c measurements and centralized assess-
ments of cardiovascular and renal biomarkers. These included lipid
profile (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycer-
ides), high sensitivity C-reactive protein, asymmetric dimethylarginine,
symmetric dimethylarginine, creatinine, and cystatin C. Samples col-
lected at baseline stored at −80C were also used to measure bio-
markers for the present study.
2.1.2 | Follow-up visits
Every 6 months: Three early morning urines were collected for central
assessment of ACR; and height, weight, waist circumference, blood
pressure, and smoking status were recorded; blood samples were
taken for local HbA1c. Blood samples were also collected for central-
ized measurements of renal and cardiovascular markers as at baseline.
2.2 | Biomarkers
Biomarkers were measured from participants' baseline serum sample
with multiplexed enzyme linked immunoabsorbent assays (ELISAs)
using Luminex technology at the CLIA certified Myriad RBM labora-
tory (Austin, TX). This panel of 35 biomarkers included those previ-
ously analyzed by our group in two cohorts of adults with type
1 diabetes,11 along with a high-sensitivity SIMOA assay for KIM-1. A
number of quality control steps were performed prior to the statistical
analysis stage. This led to excluding 10 biomarkers because more than
95% of observations were below the detection threshold: Fatty
acid-binding protein, granulocyte-macrophage colony-stimulating
factor, interferon gamma, interleukin-2, interleukin-3, interleukin-4,
interleukin-5, interleukin-7, interleukin-10, calbindin. Left-censored
values were imputed to half the detection threshold; right-
censored values were imputed to the largest value reported; values
missing at random were imputed to the median. The final number of
biomarkers included in the analyses was 25; they are listed in
Supplementary Table S1.
2.3 | Biochemistry
Urinary albumin and creatinine, plasma creatinine, and serum lipid
levels were assessed in a central laboratory (WellChild Laboratory,
Evelina London Children's Hospital), as previously described in
detail.13 Urine albumin was measured using nephelometric immunoas-
say according to the manufacturer's instructions (Siemens BN Pros-
pec, www.siemens.com), with the initial dilution set to 1:1. Urine
albumin concentrations below the limit of quantitation of nephelome-
try, typically <2.1 mg/L, were measured using an ELISA. Between
batch imprecision for the BN Prospec was 3.7% at 4.16 mg/L (n = 51),
2.9% at 19.0 mg/L (n = 55), and 2.9% at 144 mg/L (n = 54). Between
batch imprecision on the ELISA at <2.1 mg/L was <15%. Urine creati-
nine was measured using a chromatographic stable isotope dilution
electrospray mass spectrometry-mass spectrometry (MSMS) method
on an AB SCIEX API5000 (www.absciex.com). Between batch impreci-
sion (n = 48) was 2.6% at 6.89 mmol/L and 3.3% at 17.4 mmol/L.
Plasma creatinine was measured using a reference stable isotope dilu-
tion electrospray MSMS as previously described. NIST SRM 967 Cre-
atinine in Frozen Human Serum quality controls (www.nist.gov) were
included in each analytical batch. Between batch imprecision (n = 30)
was 2.8% at 66.1 μmol/L (NIST SRM 967 I) and 2.5% at 333.3 μmol/L
(NIST SRM 967 II). Lipid levels were measured at the central labora-
tory using standardized methods, as previously reported.13 HbA1c
was measured in the local laboratories using DCCT aligned assays.
2.4 | Renal outcomes
Estimated GFR (eGFR) was calculated with a modified Schwartz for-
mula (42*height/creatinine).14 “Baseline eGFR” was the measurement
at the baseline study visit, whereas “achieved eGFR” was defined as
the mean/median eGFR reading of the last 6 months of follow-up.
eGFR trajectories were calculated for each participant by a linear
slope, as for previous studies in adult cohorts with type 1 diabetes,11
and two phenotypes were defined: “rapid decliners”, including partici-
pants with eGFR slopes <−3 mL/min/1.73m2 per year; and “rapid
increasers” for participants with eGFR slopes >3 mL/min/1.73m2 per
year. Incident hyperfiltration was defined as having an eGFR
>135 mL/min/1.73m2 at any time during follow-up.
ACR was calculated as the geometric mean of three consecutive
early morning urine samples and microalbuminuria defined as an ACR
>3.5 (males) or > 4 (females) mg/mmol in at least two out of three
samples.13 Incident microalbuminuria was defined as being
normoalbuminuric at baseline and having received a label of micro-
albuminuric at any time during follow-up.
2.5 | Comparison with an adult cohort with type
1 diabetes
We compared the results for the biomarkers measured in the AdDIT
population with those obtained from a large prospective cohort study
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of adults with type 1 diabetes, the Scottish Diabetes Research Net-
work Type 1 Bioresource (SDRNT1BIO).11 In 859 individuals from the
SDRNT1BIO cohort, with eGFR between 30 and 75 mL/min/1.73 m2
at study biosample date and with at least three prospective eGFR
determinations over a period of at least 2 years or incident ESRD, the
same Luminex platform was used to measure the same biomarkers as
in AdDIT.11 eGFR in SDRNT1BIO was calculated with the CKD-EPI
equation using serum and plasma creatinine values retrieved retro-
spectively and prospectively from medical records (but excluding
readings concurrent with hospital admissions).11
2.6 | Statistical analysis
Data are summarized as median [interquartile range (IQR)] unless oth-
erwise specified.
Biomarkers were independently evaluated in linear and logistic
regression models adjusted for age, sex, diabetes duration, and base-
line eGFR (basic covariates). For models of prospective slopes, the
basic covariates also included the length of follow-up. To incorporate
more information about past and current status of renal function, we
also considered models including baseline ACR alongside the basic set
of covariates.
We further adjusted models for body mass index, systolic blood
pressure, diastolic blood pressure, HbA1c, HDL-cholesterol, total
cholesterol (full covariates). To exclude a potential effect of treatment
in participants included in the intervention arm of the AdDIT trial,
additional models adjusting for treatment were also included. All con-
tinuous variables were gaussianized prior to fitting the models and
standardized to zero mean and unit SD. For each renal outcome we
performed a cross-validated forward selection over the set of bio-
markers adjusted for age, sex, duration, eGFR, and follow-up time
using the R package nestfs (https://CRAN.R-project.org/package=
nestfs, version 0.9.1) set to terminate when the difference in valida-
tion log-likelihood is less than 2. The increment in the prediction of
being a rapid decliner and rapid increaser achieved by the panels was
assessed by examining the change in area under the receiver (AUC)
operating characteristics curves, when the biomarker panel was added
to the set of clinical covariates. Associations were declared significant
at a Bonferroni-corrected P < .002 (0.05/25).
3 | RESULTS
3.1.1. | Participants characteristics
The clinical and biochemical characteristics of study participants are
reported in Table 1. The study population included 553 adolescents
(45.2% females) with a median [interquartile range] age at baseline of
13.9 [12.6, 15.2] years and diabetes duration of 5.4 [3.4, 8.2] years.
TABLE 1 Baseline characteristics of the study population
All (n = 553) Rapid increasers (n = 42) Rapid decliners (n = 274) Rest (n = 237)
Age (y) 13.9 (12.6, 15.2) 14.9 (12.6, 15.8) 13.6 (12.5, 14.6) 14.4 (13.0, 15.7)
Sex (female) (%) 45.2 61.9 42.7 45.1
Diabetes duration (y) 5.4 (3.4, 8.2) 6.0 (3.3, 8.3) 5.4 (3.2, 7.9) 5.3 (3.6, 8.7)
HbA1c (mmol/mol) 67.2 (59.6, 77.1) 74.9 (65.6, 81.2) 65.0 (58.5, 74.9) 67.2 (61.8, 77.3)
Body mass index (kg/m2) 20.7 (18.7, 23.3) 20.8 (18.9, 23.7) 20.2 (18.6, 22.6) 21.3 (19.1, 24.2)
HDL-C (mmol/l) 1.5 (1.3, 1.8) 1.5 (1.3, 1.8) 1.6 (1.3, 1.8) 1.5 (1.2, 1.7)
Total cholesterol (mmol/L) 4.4 (3.8, 4.9) 4.4 (4.0, 4.9) 4.4 (3.9, 4.9) 4.3 (3.8, 4.8)
Systolic blood pressure (mm Hg) 115.5 (108.5, 123.0) 116.2 (107.4, 121.5) 115.0 (108.5, 122.0) 116.0 (109.0, 126.0)
Diastolic blood pressure (mm Hg) 66.5 (61.0, 73.0) 67.2 (61.0, 75.0) 66.5 (60.6, 72.4) 66.5 (61.0, 73.0)
Albumin/creatinine ratio (mg/mmol) 1.1 (0.7, 1.5) 1.1 (0.8, 1.5) 1.0 (0.7, 1.4) 1.1 (0.8, 1.6)
ACR category (Normo/Micro/Macro) 96.4/3.6/0 100/0/0 97.8/2.2/0 94.1/5.9/0
Length of follow-up (y) 3.9 (3.1, 4.1) 3.5 (2.9, 3.9) 3.9 (3.1, 4.1) 3.9 (3.2, 4.1)
eGFR (mL/min/1.73m2) 133.3 (119.2, 151.2) 127.6 (114.9, 144.9) 141.7 (123.1, 160.5) 127.8 (114.9, 141.0)
eGFR slope (mL/min/1.73m2/y) −4.0 (−7.1, −0.5) 5.1 (3.9, 8.5) −6.6 (−9.5, −4.7) −0.6 (−1.9, 0.7)
Rapid decliners (GFRs slope < −3) (%) 49.5 0 100 0
Rapid increasers (GFRs slope > 3) (%) 7.6 100 0 0
Incident microalbuminuria (%) 13.2 16.7 12.4 15.8
Incident hyperfiltration (%) 58.8 83.3 63.5 48.9
Current smoker (%) 1.1 2.4 0.7 1.3
Treatment group (A, B, C, D) (%) 42.3/18.6/19.2/19.9 33.3/26.2/21.4/19.0 43.4/16.8/19.0/20.8 42.6/19.4/19.0/19.0
Note: Data are n (%) or median (interquartile range). A: placebo/placebo or untreated, B: ACEInhibitor+placebo, C: ACEInhibitor+statin, D: statin+placebo.
Abbreviations: ACR, albumin/creatinine ratio; eGFR, estimated glomerular filtration rate.
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At baseline median ACR was 1.1 [0.7, 1.5] mg/mmol and 96.4% of the
study participants had an ACR in the normoalbuminuria range. During
the study period, 13.2% of the study participants developed
microalbuminuria in at least one study visit. Median eGFR at baseline
was 133 [119, 151] ml/min/1.73 m2 and median eGFR slopes −4.0
[−7.1, −0.5] mL/min/1.73 m2.
As reported in Table 1, out of 553 adolescents, 42 (7.6%) were
classified as “rapid increasers” and 274 (49.5%) as “rapid decliners”.
The 'rapid increasers' group differed from the rest of the study popu-
lation for a higher percentage of females and smokers, slightly longer
diabetes duration, higher HbA1c at baseline. In contrasts, the rapid
decliner' group mainly differed for a higher eGFR at baseline com-
pared to the rest of the study population.
3.1 | Biomarkers
Supplementary Table S1 shows the full list of the biomarkers mea-
sured, which passed quality control checks and were included in sub-
sequent analyses, with median levels and IQR. Supplementary
Figure S1 shows the correlation matrix of the biomarkers with each
other and with eGFR and ACR.
3.1.1 | Cross-sectional associations between
biomarkers and HbA1c at baseline
In regression models adjusted for age, sex and diabetes duration, sig-
nificant positive associations (at a P value <.002) were found between
HbA1c and nine biomarkers, such as kidney injury molecule-1, fibro-
blast growth factor-21, alpha-1 microglobulin, fibroblast growth
factor-23, tissue inhibitor of metalloproteinases 1, clusterin, growth-
regulated alpha-protein, interleukin-18, interleukin-1 receptor type
1, whereas the biomarker osteopontin showed a negative association
with HbA1c (Supplementary Table S2).
3.1.2 | Cross-sectional associations between
biomarkers and eGFR
When modeling baseline eGFR, and after adjusting for basic clinical
covariates (age, sex, and diabetes duration), three biomarkers reached
the statistically significant threshold of P < .002, and all showed a neg-
ative association with eGFR: trefoil factor-3 (B coefficient [95%CI]:
−0.19 [−0.27, −0.12], P = 7.0 × 10−7), cystatin C (−0.18 [−0.26,
−0.11], P = 5.1 × 10−6); and beta-2 microglobulin (−0.12 [−0.20,
−0.05], P = 1.6 × 10−3) (Table 2). The results remained unchanged in
models adjusted for baseline ACR and the full clinical covariates (data
not shown).
3.1.3 | Biomarkers associated with achieved eGFR
and eGFR changes during follow up
Final achieved eGFR was inversely associated with two biomarkers
(P < .002): osteopontin (−0.21 [−0.28, −0.14], P = 2.3 × 10−8) and
cystatin C (−0.16 [−0.22, −0.09]), P = 1.6 × 10−6), after adjustments
for the basic clinical covariates (age, sex and diabetes duration), base-
line eGFR, and length of follow-up (Table 3). These results remained
unchanged in models adjusted for baseline ACR, the full set of clinical
covariates and treatment (data not shown).
In logistic regression models, the rapid decliner phenotype was
positively associated to osteopontin with an odds ratio of 1.83 [95%
CI 1.42, 2.41] (P = 7.3 × 10−6), adjusted for the basic clinical
covariates, baseline eGFR, and length of follow-up (Table 4). In similar
logistic regression models, the rapid increaser phenotype was associ-
ated with fibroblast growth factor-23 (1.59 [1.23, 2.04],
P = 2.6 × 10−4) and inversely associated with osteopontin (0.58 [1.42,
0.80], (P = 2.6 × 10−4)) (Table 4).
TABLE 2 Cross-sectional associations of each biomarker
(considered separately) with baseline eGFR, from liner regression
models adjusted for age, sex, and diabetes duration
Biomarker Coefficient (95% CI) P-value
Trefoil factor 3 −0.19 (−0.27, −0.12) 7.0 × 10−07
Cystatin-C −0.18 (−0.26, −0.11) 5.1 × 10−06
Beta-2-microglobulin −0.12 (−0.20, −0.05) 1.6 × 10−03
CD27 antigen −0.10 (−0.17, −0.02) 1.2 × 10−02
Latency-associated-peptide 0.09 (0.01, 0.17) 2.4 × 10−02
Growth-regulated alpha
protein
0.08 (0.01, 0.16) 3.6 × 10−02
Eotaxin-2 −0.05 (−0.13, 0.02) 1.7 × 10−01
Fibroblast growth factor 21 0.06 (−0.02, 0.14) 1.5 × 10−01
Interleukin-6 −0.06 (−0.13, 0.02) 1.4 × 10−01
Insulin-like growth factor-
binding protein 7
−0.04 (−0.12, 0.03) 2.7 × 10−01
Interleukin-1 receptor type 1 0.04 (−0.03, 0.12) 2.5 × 10−01
Lectin-like oxidized LDL
receptor 1
−0.05 (−0.12, 0.03) 2.4 × 10−01
Interleukin-2 receptor alpha 0.03 (−0.05, 0.10) 5.3 × 10−01
Neutrophil gelatinase-
associated lipocalin
−0.03 (−0.11, 0.04) 3.9 × 10−01
Tamm-horsfall urinary
glycoprotein
−0.04 (−0.11, 0.04) 3.6 × 10−01
Alpha-1-microglobulin 0.03 (−0.04, 0.11) 3.8 × 10−01
Clusterin 0.03 (−0.04, 0.11) 4.1 × 10−01
Osteopontin −0.03 (−0.12, 0.06) 5.1 × 10−01
Tissue inhibitor of
metalloproteinases 1
0.03 (−0.04, 0.11) 4.1 × 10−01
Fibroblast growth factor 23 0.01 (−0.06, 0.09) 7.6 × 10−01
Interleukin-1 receptor type 2 −0.02 (−0.09, 0.06) 7.0 × 10−01
Vascular endothelial growth
factor
0.02 (−0.05, 0.10) 5.3 × 10−01
Kidney injury molecule-1 −0.01 (−0.08, 0.07) 8.6 × 10−01
Interleukin-18 0.00 (−0.08, 0.07) 9.3 × 10−01
Interleukin-8 0.00 (−0.07, 0.08) 9.4 × 10−01
Note: Regression coefficients are per unit of SD of gaussianised biomarker.
Abbreviation: eGFR, estimated glomerular filtration rate.
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When considering the rapid decliners phenotype as outcome,
the forward selected panel only included osteopontin and improved
the AUC beyond basic clinical covariates from 0.689 to 0.717. For the
rapid increaser phenotype, forward selection chose in order
osteopontin, interleukin-18, eotaxin-2 and fibroblast growth factor-
23, thus marginally improving the AUC from 0.645 to 0.679.
3.1.4 | Comparison with an adult cohort with type
1 diabetes
When comparing the AdDIT biomarker results with those obtained in
the adult SDRNT1BIO cohort (Supplementary Table S3), the negative
TABLE 3 Association of each biomarker with achieved eGFR
from liner regression models adjusted for age, sex, diabetes duration,
baseline eGFR, and length of follow up
Biomarker Coefficient (95%CI) P-value
Osteopontin −0.21 (−0.28, −0.14) 2.3 × 10−08
Cystatin-C −0.16 (−0.22, −0.09) 1.6 × 10−06
Insulin-like growth factor-
binding protein 7
−0.10 (−0.16, −0.03) 3.1 × 10−03
CD27 antigen −0.08 (−0.15, −0.02) 7.2 × 10−03
Fibroblast growth factor 23 0.08 (0.02, 0.14) 9.6 × 10−03
Growth-regulated alpha
protein
0.08 (0.02, 0.15) 9.8 × 10−03
Fibroblast growth factor 21 0.07 (0.01, 0.13) 3.0 × 10−02
Interleukin-2 receptor alpha −0.07 (−0.13, −0.01) 2.8 × 10−02
Beta-2-microglobulin −0.06 (−0.12, 0.00) 5.8 × 10−02
Kidney injury molecule-1 0.04 (−0.02, 0.10) 2.3 × 10−01
Trefoil factor 3 −0.04 (−0.10, 0.03) 2.4 × 10−01
Eotaxin-2 −0.03 (−0.09, 0.03) 2.9 × 10−01
Interleukin-6 0.03 (−0.03, 0.09) 3.4 × 10−01
Lectin-like oxidized LDL
receptor 1
0.03 (−0.03, 0.10) 3.0 × 10−01
Alpha-1-microglobulin −0.02 (−0.08, 0.04) 5.5 × 10−01
Interleukin-18 0.01 (−0.05, 0.08) 6.7 × 10−01
Interleukin-1 receptor type 1 −0.02 (−0.09, 0.04) 4.9 × 10−01
Latency-associated-peptide −0.02 (−0.08, 0.04) 5.5 × 10−01
Tissue inhibitor of
metalloproteinases 1
0.02 (−0.05, 0.08) 6.1 × 10−01
ascular endothelial growth
factor
0.02 (−0.04, 0.08) 5.0 × 10−01
lusterin −0.01 (−0.07, 0.06) 8.7 × 10−01
Interleukin-1 receptor type 2 −0.01 (−0.08, 0.05) 7.0 × 10−01
Interleukin-8 0.00 (−0.06, 0.07) 9.5 × 10−01
Neutrophil gelatinase-
associated lipocalin
0.00 (−0.06, 0.07) 9.5 × 10−01
Tamm-horsfall urinary
glycoprotein
0.00 (−0.06, 0.06) 9.5 × 10−01
Note: Regression coefficients are per unit of SD of gaussianised biomarker.
Abbreviation: eGFR, estimated glomerular filtration rate.
TABLE 4 Association of each biomarker with rapid decliner (A) and
rapid increaser (B) phenotypes from logistic regression models adjusted
for age, sex, diabetes duration, baseline eGFR and length of follow up
A
Biomarker
Odds ratio
(95% CI) P-value
Osteopontin 1.83 (1.42, 2.41) 7.3 × 10−06
Cystatin-C 1.26 (1.02, 1.56) 3.0 × 10−02
Insulin-like growth factor-binding
protein 7
1.25 (1.02, 1.55) 3.5 × 10−02
Growth-regulated alpha protein 0.80 (0.65, 0.98) 2.8 × 10−02
eutrophil gelatinase-associated
lipocalin
0.82 (0.67, 1.00) 5.6 × 10−02
Fibroblast growth factor 21 0.84 (0.69, 1.02) 8.3 × 10−02
Interleukin-1 receptor type 2 1.19 (0.98, 1.46) 8.1 × 10−02
Lectin-like oxidized LDL receptor 1 0.85 (0.70, 1.04) 1.2 × 10−01
Tissue inhibitor of
metalloproteinases 1
0.86 (0.70, 1.04) 1.2 × 10−01
Tamm-horsfall urinary glycoprotein 1.16 (0.95, 1.42) 1.4 × 10−01
Fibroblast growth factor 23 0.87 (0.71, 1.06) 1.6 × 10−01
Interleukin-18 0.89 (0.73, 1.09) 2.7 × 10−01
Interleukin-8 0.89 (0.73, 1.09) 2.6 × 10−01
Interleukin-6 0.91 (0.75, 1.11) 3.6 × 10−01
Interleukin-2 receptor alpha 1.08 (0.88, 1.32) 4.8 × 10−01
Alpha-1-microglobulin 0.93 (0.76, 1.14) 4.9 × 10−01
Beta-2-microglobulin 0.93 (0.75, 1.13) 4.7 × 10−01
Vascular endothelial growth factor 0.95 (0.78, 1.16) 6.0 × 10−01
Trefoil factor 3 0.95 (0.78, 1.16) 6.3 × 10−01
Latency-associated-peptide 1.05 (0.86, 1.28) 6.6 × 10−01
CD27 antigen 1.03 (0.85, 1.26) 7.5 × 10−01
Clusterin 0.99 (0.81, 1.20) 8.8 × 10−01
Eotaxin-2 0.99 (0.81, 1.21) 9.4 × 10−01
Interleukin-1 receptor type 1 1.01 (0.82, 1.23) 9.6 × 10−01
Kidney injury molecule-1 1.00 (0.82, 1.22) 9.9 × 10−01
B
Biomarker
Odds ratio
(95% CI) P-value
Osteopontin 0.58 (0.42, 0.80) 9.5 × 10−04
Fibroblast growth factor 23 1.59 (1.23, 2.04) 2.6 × 10−04
Lectin-like oxidized LDL receptor
1
1.55 (1.11, 2.16) 9.6 × 10−03
otaxin-2 0.66 (0.47, 0.91) 1.4 × 10−02
Cystatin-C 0.69 (0.49, 0.97) 3.2 × 10−02
Growth-regulated alpha protein 1.42 (1.03, 1.95) 3.2 × 10−02
Interleukin-18 1.36 (0.99, 1.89) 6.0 × 10−02
Neutrophil gelatinase-associated
lipocalin
1.38 (0.99, 1.92) 5.6 × 10−02
Alpha-1-microglobulin 1.31 (0.92, 1.93) 1.5 × 10−01
Fibroblast growth factor 21 1.25 (0.89, 1.78) 2.0 × 10−01
Vascular endothelial growth factor 1.26 (0.92, 1.75) 1.5 × 10−01
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associations between baseline eGFR and trefoil factor-3, cystatin C,
and beta-2 microglobulin were also present in the adult cohort. Simi-
larly, when comparing the results for the final achieved eGFR,
ostepontin and cystatin C were also negatively associated with this
outcome in the adult cohort. However, in the adult cohort several
additional biomarkers emerged to be associated with eGFR, among
them alpha 1-microglobulin, CD27 antigen, kidney injury molecule-1,
which were not identified in the younger AdDIT cohort (Figure 1A,B).
No associations were found between biomarkers and ACR at
baseline or during follow-up in the AdDIT cohort, whereas several bio-
markers were associated with ACR in the adult cohort (Figure 1C).
4 | DISCUSSION
In this population of adolescents with type 1 diabetes, predominantly
normoalbuminuric at baseline, and showing high rates of hyper-
filtration, trefoil factor-3, cystatin C and beta-2 microglobulin were
negatively associated with eGFR at baseline, whereas osteopontin
and cystatin C were associated with faster eGFR declines, and fibro-
blast growth factor-23 with more rapid increases in eGFR over a
median follow up period of 3.9 years.
In adolescents with type 1 diabetes, changes in GFR, mainly in
the form of hyperfiltration, are common, and they are partly related to
the diabetes milieu, with hyperglycemia being a main driver for hyper-
filtration, together with the effect of pubertal physical and hormonal
changes.3,8 In the present study, high rates of hyperfiltration were evi-
dent at baseline, and they persisted during the study period.
Decreased levels of trefoil factor-3, cystatin C, and beta-2 micro-
globulin were associated with higher eGFR levels at baseline, likely
reflecting that these are renal biomarkers of filtration.
Beta-2 microglobulin is considered a surrogate marker for eGFR being
freely filtered by the glomerulus and then almost completely reabsorbed
by the proximal tubule.15 In adults with type 2 diabetes, beta-2 micro-
globulin has emerged as a predictor of renal function decline16,17 and
ESRD.18 In the present study, we could not confirm an association
between beta-2 microglobulin and changes in eGFR during follow-up, and
this might be due to differences in the age range and/or diabetes duration
of our study population and the relatively preserved eGFR during follow-
up compared to participants recruited in previous studies, or alternatively
differences between subjects with type 1 and type 2 diabetes.
The other biomarker associated with eGFR at baseline was trefoil
factor-3, but again this biomarker was not associated with prospective
changes in eGFR. In a recent study, based on a Mendelian randomiza-
tion approach, trefoil factor-3 emerged as a valuable diagnostic
marker for early stages of kidney diseases in individuals with type
2 diabetes as well as in those with prediabetes, and levels of this bio-
marker increased as a result of decreased eGFR.19 Trefoil factor-3 also
improved the discrimination for chronic kidney disease in addition to
eGFR alone, highlighting its potential as a predictive biomarker.19
In the present study, some other interesting associations were
found between some of the biomarkers measured at baseline and pro-
spective changes in eGFR. One biomarker associated with changes in
eGFR during follow-up was osteopontin, with increased levels associ-
ated with greater declines in eGFR and a lower eGFR by the end of the
follow-up period. Osteopontin is a phosphorylated sialic acid-rich non-
collagenous matricellular protein, named for its function as a bridge
between cells and minerals in the bones.20 This protein has been asso-
ciated with cardiovascular disease, cancer, diabetes, and kidney stone
diseases and is implicated in the process of inflammation, biomineraliza-
tion, cell viability, and wound healing.20 Circulating osteopontin levels
are increased in patients with diabetes compared to healthy controls
and are related to insulin resistance, inflammation, vascular calcifica-
tion.20 Studies in adults with type 2 diabetes have reported an associa-
tion with retinopathy as well as with progression of diabetic
nephropathy and cardiovascular disease.21,22 In type 1 diabetes, data
from the large FinnDiane study have shown that osteopontin is an
independent predictor of incident microalbuminuria and cardiovascular
events.23 In a small cross-sectional pediatric study, osteopontin was
found to be elevated in children and adolescents with type 1 diabetes
compared to healthy controls, and to be related to subclinical signs of
vascular disease, such as increased intima-media thickness, as well as to
urinary albumin excretion.24 These data suggest that osteopontin could
be a potential common biomarker for renal and cardiovascular compli-
cations, reflecting similar mechanisms underlining these complications.
Cystatin C was also found to be a predictor of decline in eGFR
during the study period as already well described in adults.25 In addi-
tion, higher levels of fibroblast growth factor-23 were associated with
a higher eGFR increases over time. Fibroblast growth factor-23 is a
known key regulator of phosphorus homeostasis and it has also been
suggested to be implicated in inflammation, immunosuppression, and
TABLE 4 (Continued)
B
Biomarker
Odds ratio
(95% CI) P-value
Clusterin 1.26 (0.91, 1.74) 1.6 × 10−01
Interleukin-1 receptor type 1 1.22 (0.88, 1.72) 2.5 × 10−01
Interleukin-2 receptor alpha 0.81 (0.57, 1.13) 2.2 × 10−01
Insulin-like growth factor-binding
protein 7
0.84 (0.61, 1.13) 2.6 × 10−01
Interleukin-6 1.21 (0.89, 1.54) 1.5 × 10−01
CD27 antigen 0.89 (0.64, 1.22) 4.8 × 10−01
Latency-associated-peptide 0.91 (0.70, 1.24) 5.3 × 10−01
Kidney injury molecule-1 simoa 1.09 (0.79, 1.47) 5.8 × 10−01
Trefoil factor 3 1.09 (0.78, 1.52) 6.0 × 10−01
Interleukin-8 1.07 (0.75, 1.46) 6.9 × 10−01
Tissue inhibitor of
metalloproteinases 1
0.97 (0.69, 1.35) 8.8 × 10−01
Tamm-horsfall urinary
glycoprotein
1.03 (0.76, 1.42) 8.3 × 10−01
Beta-2-microglobulin 0.98 (0.70, 1.39) 9.2 × 10−01
Interleukin-1 receptor type 2 0.99 (0.73, 1.37) 9.4 × 10−01
Note: Odds ratios are per unit of SD of gaussianised biomarker.
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cardiovascular disease.26 Of interest, it has also emerged as a new risk
factor in chronic kidney disease, being an independent predictor of
progression of chronic kidney disease in people without diabetes.27 In
patients with type 2 diabetes and macroalbuminuria, fibroblast growth
factor-23 has been associated with renal outcomes,27,28 although
there is a need for additional studies in type 1 diabetes to explore its
longitudinal changes and potential value as a biomarker of renal
function.
F IGURE 1 Comparisons between
biomarkers in the AdDIT and
SDRNT1BIO cohorts: (A) Association
with baseline eGFR in AdDIT and
SDRNT1BIO (basic covariate models).
(B) Association with achieved eGFR in
AdDIT and SDRNT1BIO (basic
covariate models). (C) Association
with baseline ACR in AdDIT and
SDRNT1BIO (basic covariate models).
ACR, albumin/creatinine ratio; AdDIT,
Adolescent Type 1 Diabetes Cardio-
Renal Intervention Trial; eGFR,
estimated glomerular filtration rate;
SDRNT1BIO, Scottish Diabetes
Research Network Type
1 Bioresource
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Some interesting findings of the present study emerged from
the comparisons of the results of the same set of biomarkers in an
adult cohort with type 1 diabetes, the SDRNT1BIO.11,29
Osteopontin and cystatin C were also found to be negatively associ-
ated with eGFR in the adult cohort. However, in the same adult
cohort, additional biomarkers were associated with eGFR at base-
line and predict its prospective changes, and some biomarkers even
showed an opposite association compared with the adolescent
cohort. These discordant findings between adults and adolescents
with type 1 diabetes could be related to differences in the age and
diabetes duration between the two study populations, or in the
ontology of changes in renal function through adolescence into
adult life. Regarding decline in eGFR, the fall detected in our adoles-
cent cohort mainly reflected a reduction of the initial hyperfiltration
and therefore a return of GFR to within a normal range, as con-
firmed by the higher eGFR at baseline in the “rapid decliner” group
compared to the rest of the study population. This could be consid-
ered a physiological decline, occurring mainly once pubertal devel-
opment has been completed,3 and could reflect a different
underlining process than the one leading to the decline occurring in
adult cohorts. The present cohort of adolescents also differed from
adult cohorts with type 1 diabetes for the presence of a subgroup
with rapid increasing GFR during follow up. This subgroup was char-
acterized by a greater number of females, higher HbA1c at baseline,
longer diabetes duration and higher percentages of smokers. This
group confirms that hyperfiltration is a common feature in adoles-
cents with type 1 diabetes whereas it has less often observed in
adult cohorts.9
In this young cohort of adolescents with type 1 diabetes, there
were no significant associations between the assessed biomarkers
and ACR. This was in contrast with the results from the adult cohort
where the same panel of biomarkers was evaluated. These differences
are likely explained by the fact that the AdDIT cohort was predomi-
nantly normoalbuminuric at baseline.
It needs to be acknowledged that, in the present study, we
assessed changes in renal function during a short period of follow up
and, therefore power to detect associations with eGFR decline was
limited. Only longer-term follow-up will provide further insights on
the potential predictive values of the assessed biomarkers in relation
to hard renal outcomes and allow better comparisons with adult
cohorts.
Another potential study limitation was the use of an estimate of
GFR to assess renal function. However, this was based on a creatinine
formula derived from our own laboratory from a population of adoles-
cents with type 1 diabetes. This formula can be easily implemented
into clinical practice as well as for repeated measurements of GFR,
being based on the routinely measured creatinine. However, this for-
mula differs from that used in SDRT1BIO adult cohort, which was one
of the standard formulas recommended in adults. This highlights a
common issue in longitudinal studies, when pediatric participants
transition into adulthood, with the need of changing the formula used
to estimate GFR and a potential bias due to differences in formulas
performance.
5 | CONCLUSION
In this young population with type 1 diabetes and high rates of hyper-
filtration, osteopontin was the most consistent biomarker associated
with prospective changes in eGFR, although there was only a modest
increment in predicting future eGFR changes over clinical variables
and baseline eGFR and ACR. Fibroblast growth factor-23 was associ-
ated with rapid eGFR increases, whereas trefoil factor-3, cystatin C,
and beta-2 microglobulin were only associated with eGFR at baseline.
Further follow up of the AdDIT cohort will allow us to explore the
potential predictive value of these biomarkers on long-term changes
in eGFR and ACR.
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